Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2012

View Archived Issues

New S1P1 receptor agonists prepared by Allergan

Novel PI3K-alpha/mTORC1 inhibitors disclosed by Exelixis

Phase III study planned for MOD-4023

Novo Nordisk presents new long-acting drug for growth hormone deficiency

Lilly diabetes drug substantially decreases HbA1c without delaying recovery from hypoglycemia

Amicus reports preliminary results from phase II study in Pompe's disease

AstraZeneca patents novel agents for arrhythmia

Novel TRPV1 channel antagonists developed at GlaxoSmithKline

Polish team describes new fusion proteins for cancer

Korean researchers present novel protein kinase inhibitors

Merck KGaA designs new hPDK1 inhibitors

New fusion proteins for bone disorders designed in Korea

Research collaboration begins for Parkinson's disease gene therapy

EMA issues scientific opinion on Sanofi Pasteur vaccine

QRxPharma receives complete response letter for MoxDuo

Topica launches phase IIb/III study in onychomycosis

Dosing begins in first-in-human PA-401 trial

New gevokizumab trials initiated in uveitis and erosive osteoarthritis

FDA issues safety communication on cefepime

Depomed acquires rights to liquid-filled capsule analgesic

FDA approves first new weight loss drug in 13 years

Sunesis Pharmaceuticals receives milestone payment for kinase inhibitor program

PTC Therapeutics begins open-label ataluren study

FDA grants premarket approval to noninvasive test to detect prostate cancer

Janssen-Cilag applies for European approval of canagliflozin

CHMP issues opinion on Zyclara MAA

FDA issues complete response letter for Xarelto sNDA

Favorable preclinical profile supports clinical testing of grass pollen vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...